Clinical Trials Browser

Dysgerminoma × Imatinib Mesylate × Genitourinary × Clear all

NCT00042952 2013-01-17

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Phase 2 Terminated

Dysgerminoma, Testicular Neoplasms, Seminoma